Compare Citius Pharmaceuticals Inc (CTXR) vs Fastly Inc (FSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Fastly Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Fastly Inc trades at $20.31 (market cap $3.27B). The key difference: Fastly Inc is far larger — about 223.4× Citius Pharmaceuticals Inc's market cap, and Fastly Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | FSLY | |
|---|---|---|
Market Cap | $14.64M | $3.27B |
Sector | Health | Technology |
52-Week High | $1.82 | $33.50 |
52-Week Low | $0.53 | $6.36 |
Enterprise Value | $10.86M | $3.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Fastly (FSLY) trades at $20.03, up 2.25% today, with a bullish technical signal from moving averages. The company shows improving fundamentals with Q1 2026 EPS beating expectations at $0.13 versus $0.08, and revenue growth accelerating to 20% year-over-year. Recent news highlights strategic partnerships for digital sustainability and edge AI commerce, while cash flow trends indicate potential stabilization with 2026 net cash flow projected positive at $21 million.
Outlook remains cautiously optimistic with a consensus price target of $24.25 offering 21% upside, though persistent net losses and negative ROE pose risks. Investor sentiment is mixed with 29% buy ratings amid competitive pressures in edge cloud services. Key catalysts include Q2 2026 earnings on August 5 and execution on margin expansion targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →
